Trial Profile
Revlimid, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: a Phase 2 Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Melphalan
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms REMMYDYS
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jul 2011 Planned end date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 27 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.